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Abstract
Parasites of the Leishmania genus can rapidly alter several macrophage (MØ) signalling pathways in order to tame down the
innate immune response and inflammation, therefore favouring their survival and propagation within their mammalian
host. Having recently reported that Leishmania and bacterial LPS generate a significantly stronger inflammatory response in
animals and phagocytes functionally deficient for the Src homology 2 domain-containing protein tyrosine phosphatase
(SHP-1), we hypothesized that Leishmania could exploit SHP-1 to inactivate key kinases involved in Toll-like receptor (TLR)
signalling and innate immunity such as IL-1 receptor-associated kinase 1 (IRAK-1). Here we show that upon infection, SHP-1
rapidly binds to IRAK-1, completely inactivating its intrinsic kinase activity and any further LPS-mediated activation as well as
MØ functions. We also demonstrate that the SHP-1/IRAK-1 interaction occurs via an evolutionarily conserved ITIM-like motif
found in the kinase domain of IRAK-1, which we named KTIM (Kinase Tyrosyl-based Inhibitory Motif). This regulatory motif
appeared in early vertebrates and is not found in any other IRAK family member. Our study additionally reveals that several
other kinases (e.g. Erk1/2, IKKa/b) involved in downstream TLR signalling also bear KTIMs in their kinase domains and
interact with SHP-1. We thus provide the first demonstration that a pathogen can exploit a host protein tyrosine
phosphatase, namely SHP-1, to directly inactivate IRAK-1 through a generally conserved KTIM motif.
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Introduction
Innate inflammatory responses play a critical role in controlling
pathogens [1]. However, protozoan parasites such as Leishmania
evolved strategies to avoid phagocyte activation by seizing control
of key signalling pathways, therefore favouring their invasion and
survival within the host cell [2]. We recently reported that the
protein tyrosine phosphatase (PTP) SHP-1 plays a pivotal role in
taming down phagocyte-mediated inflammatory responses [3].
For instance, we showed that in the absence of SHP-1, several pro-
inflammatory cytokines (e.g. IL-1b, IL-6, TNFa) and chemokines,
as well as inflammatory neutrophil recruitment were all exacer-
bated by Leishmania infection [3]. Of interest, we also found that
LPS mediates an excessive inflammatory response in the absence
of SHP-1, therefore suggesting that SHP-1 could exert its negative
regulatory action via Toll like receptor (TLR) signalling.
As SHP-1 can interact with various members of the JAK and
MAP kinase families in physiological, immune response, and
infection contexts [2,3], we explored the possibility that the
capacity of Leishmania to block the macrophage (MØ) inflamma-
tory response could result from rapid IRAK-1 kinase inactivation
through SHP-1 action. This hypothesis is further reinforced by the
fact that several LPS-mediated MØ functions (e.g. TNFa, NO, IL-
12), critical for the containment of pathogens and adaptive
immune response development, are inhibited upon Leishmania
infection [2,4,5].
Whereas invertebrates depend mainly on the evolutionarily
conserved innate immune system to fight off pathogens, verte-
brates have developed a sophisticated adaptive immune system,
hence the need to regulate the innate immune response. The TLR
family has been shown to play a key role in triggering innate
immunity as well as the subsequent induction of adaptive immune
responses in vertebrates [6]. Our previous findings reporting
augmented Leishmania- and LPS-induced innate inflammatory
response in the absence of SHP-1 (PTPN6) [3], and the several
reports that key transcription factors (NF-kB and AP-1) related to
TLR signalling were strongly activated in the absence of SHP-1
[7–9], suggested the importance of SHP-1 in the negative
regulation of TLR signalling and its subsequent inflammatory
response in vertebrates. Of interest, a mutation in the PTPN6 gene
coding for SHP-1 in humans has been recently linked to Sezary
syndrome [10], a T-cell cutaneous lymphoma arising from chronic
inflammatory state.
From these observations, and given the fact that IRAK-1 serves
as a crucial kinase in all MyD88-dependent pathways leading to
the activation of innate inflammatory responses, we hypothesised
www.plosntds.org 1 December 2008 | Volume 2 | Issue 12 | e305that SHP-1 is a critical player in the negative regulation of this
kinase that can be exploited by Leishmania. For instance, until
recently there was no indication that SHP-1 could interact with
IRAK-1. However, a recent study by Cao’s laboratory [11]
provided strong evidence that SHP-1 can interact with IRAK-1.
Here, we provide evidence that SHP-1 negatively regulates
IRAK-1 intrinsic kinase activity in its resting state and upon
Leishmania infection through binding to an evolutionarily conserved
ITIM-like motif located within IRAK-1’s kinase domain. In
addition, it is important to stress that this is the first mention of this
motif to be found within a kinase, as to date it has only been found
within the intracytoplasmic portion of immunoglobin (Ig)-like
receptors. Of interest, we also discovered that this ITIM-like motif
was present in several other kinases. Finally, our study also
provides evidence from in silico sequence analyses that both IRAK-
1 and SHP-1 evolutionarily emerged in vertebrates concomitantly
with the development of a better-controlled innate immune
response. Therefore the appearance of this key interaction in
early vertebrates may have also contributed to the development of
the more complex adaptive immune response.
Materials and Methods
Cell culture and reagents
The immortalized me-3 (SHP-1
2/2) and LM-1 (WT) bone
marrow-derived MØs (BMDMs) were generated from motheaten
mice (Ptpn6
me/me; C3HeBFeJ me/me) and their respective wild-type
littermates (C3HeBFeJ me/+) as described [7]. The immortalized
B10R BMDMs were derived from B10A.Bcg
r mice [12]. L929
cells used for the TNF bioassays were grown in RPMI-1640
medium (5% FBS). MØ-activating lipopeptide-2 (MALP-2) and
lipopolysaccharide (LPS) from E.coli were purchased from Alexis
Biochemicals, San Diego, CA. Flagellin and CpG DNA were
purchased from Invivogen, San Diego, CA. IRAK1/4 inhibitor
(N-(2-Morpholinylethyl)-2-(3-nitrobenzoylamido)-benzimidazole)
was purchased from Calbiochem, La Jolla, CA.
In vitro infection
L. donovani infantum, L. mexicana (MNYC/BZ/62/M379), L. major
Friedlin strain (MHOM/JL/80/Friedlin), and L. tarentolae strain
TAR II promastigotes were kept in SDM medium (10% FBS), and
stationary phase parasites were used to infect cells in a parasite to
MØ ratio of 20:1. Non-internalized parasites were removed by
washing the plates with phosphate-buffered saline (PBS), after
which MØs were collected for subsequent experiments.
Western blot analysis
Western blotting was performed as previously described [13].
Proteins were detected using antibodies directed against IRAK-1
(generated in the laboratory of Dr. Akira), SHP-1 and phospho-
tyrosine (clone 4G10) (Upstate, Charlottesville, VA), and actin
(Sigma-Aldrich, ON, Canada). Proteins were detected using an
anti-rabbit or anti-mouse horseradish peroxidase (HRP)-conjugat-
ed antibody (Amersham, QC, Canada) and visualized using ECL
western blotting detection system (Amersham).
IRAK-1/IRAK-4 kinase assay
6610
6 MØs were lysed in cold lysis buffer (20mM Tris (pH 7.5),
1mM EDTA, 150mM NaCl, 1% Igepal, 10mM b-glycerophosphate,
1mM sodium orthovanadate, 25 mg/ml aprotinin and 25 mg/ml
leupeptin). Lysates were precleared with protein A/G agarose beads
(Santa Cruz, CA). Samples were then centrifuged (13,0006 g,
10 min) and supernatants kept. IRAK-1 or IRAK-4 antibody and
protein A/G agarose beads were added to the supernatant and
samples were incubated O/N at 4uC. Beads were spun down and
washed with the lysis buffer described above, followed by washes with
the kinase assay buffer (20mM HEPES pH 7.5, 20mM MgCl2,3 m M
MnCl2, and 10mM b-glycerophosphate). Kinase assay buffer (20 ml)
containing 10 mCi of c-
32P (Amersham) was then added to the beads
and samples incubated (30 min, 30uC). The reaction was stopped by
the addition of 46sample loading buffer (12.5% Tris-HCl (pH 6.8),
10% glycerol, 10% SDS, 5% b-mercaptoethanol, 0.05% bromo-
phenol blue). Samples were boiled and ran on SDS-PAGE. Bands
were detected using X-ray Kodak films (Amersham) or by image
analyzer (BioRad, Canada).
In gel PTP assay
For immunoprecipitation samples, 6610
6 MØs were lysed as
described previously for the IRAK-1 kinase assay without the
addition of sodium orthovanadate to the lysis buffer. Cell lysate
controls (25 mg) were obtained using a PTP lysis buffer (50mM
Tris (pH 7.0), 0.1mM EDTA, 0.1mM EGTA, 0.1% b-mercapto-
ethanol, 1% Igepal, 25 mg/ml aprotinin and 25 mg/ml leupeptin).
Samples were loaded on a gel containing a c-
32P-labelled
poly(Glu4Tyr) peptide (Sigma-Aldrich) and the SHP-1 band was
observed by in gel PTP assay as previously described [14].
Co-immunoprecipitation
Samples were lysed in the western blot lysis buffer (no sodium
orthovanadate was added when immunoprecipitating SHP-1) and
immunoprecipitated using protein A/G agarose beads (Santa
Cruz) and 4 mg of the IRAK-1, SHP-1 antibody, or anti-rat
antibody (Sigma-Aldrich) for non-specific binding. Beads were
spun down and washed three times with lysis buffer. Beads were
resuspended in the 46 western sample loading buffer previously
described and boiled supernatants were loaded on SDS-PAGE
and western blot analysis was performed as described above.
GST pull-down assay
Wildtype mouse IRAK-1 gene and the IRAK-1 genes of the
different KTIM mutants (all in PCDNA3 vectors) were in vitro
Author Summary
Leishmania developed several methods to seize control of
macrophage signalling pathways in an effort to inactivate
their killing abilities. One effective method utilized by the
parasite is the activation of host protein tyrosine
phosphatases, specifically SHP-1. This increased phospha-
tase activity contributes to the inactivation of signalling
molecules involved in critical macrophage functions such
as NO and cytokine production. Interestingly, the absence
of SHP-1 results in stronger macrophage inflammatory
responses to a bacterial cell wall component known as LPS,
a molecule detected by macrophages through Toll-like
receptors (TLRs). This observation suggested a role for
SHP-1 in the regulation of TLR signalling. Our study reveals
that upon Leishmania infection, SHP-1 is able to rapidly
bind to and inactivate a critical kinase (IRAK-1) in this
pathway. This regulatory binding was shown to be
mediated by an evolutionarily conserved motif identified
in the kinase. This motif was also present in other kinases
involved in Toll signalling and therefore could represent a
regulatory mechanism of relevance to many kinases. This
work not only reports a unique mechanism by which
Leishmania can avoid harmful TLR signalling, but also
provides a platform on which extensive investigation on
host evasion mechanisms and regulation of cellular kinases
can be gained.
Leishmania-Induced IRAK-1 Inactivation
www.plosntds.org 2 December 2008 | Volume 2 | Issue 12 | e305translated using the Promega TNT Quick Coupled Transcrip-
tion/Translation kit (Fisher Scientific, ON, Canada) using 20 mCi
35S (Amersham). The active or the trapping mutant of GST SHP-
1 was produced in BL21 bacteria. Bacterial lysates were extracted
using the BugBuster Protein Extraction Reagent (VWR CANLAB,
ON, Canada), and the GST protein (5 mg) was pulled down from
bacterial lysates using glutathione sepharose beads (30 ml)
(Amersham). The active/trapping mutant of GST-SHP-1 bound
to glutathione beads was left to interact with immunoprecipitates
(IPs) or in vitro translated IRAK-1 protein in a PTP reaction buffer
(50mM Hepes (pH 7.5), 0.1% b-mercaptoethanol) for 1 h at RT.
When in vitro translation of IRAK-1 was performed, GST-SHP-1
was allowed to interact with IRAK-1 in a 5:1 ratio. Beads were
then spun down, washed 36 with the PTP lysis buffer, then
resuspended in 46 sample loading buffer (20 ml), boiled, and
loaded on SDS-PAGE. IRAK-1 bands were revealed by exposing
to X-ray film (Amersham).
Alkali-resistance phosphoprotein assay
Kinase assays were run on SDS-PAGE as described above, pre-
treatment image is taken by exposing the gel to a phospho-imager
screen. Next, gels were fixed overnight at RT in a 10% methanol/
7% acetic acid solution. Gels were then soaked in a 10%
glutaraldehyde solution (30 min, RT) with gentle shaking and
rinsed in water prior to incubation with KOH. The alkali
treatment of
32P-labelled IRAK-1 was performed as previously
described [15].
Generation of IRAK-1 mutants
The mouse IRAK-1 gene cloned into a PCDNA3 plasmid was
mutated at different sites within the KTIM using the QuikChange
site-directed mutagenesis kit (Stratagene, La Jolla, CA) as
instructed by the manufacturer. The primers (all synthesized by
Genome Que ´bec, Montre ´al, QC, Canada) designed to create the
mutants were:
For the tyrosine to phenylalanine mutation;
sense: 59GGCTTATACTGCCTTGTTTTTGGCTTCTTGC-
CCAATGG39;
anti-sense: 59CCATTGGGCAAGAAGCCAAAAACAAGGC-
AGTATAAGCC39.
For the leucine to methionine mutation;
sense: 59GGCTTATACTGCCTTGTTTATGGCTTCATG-
CCCAATGG39;
anti-sense: 59CCATTGGGCATGAAGCCATAAACAAGG-
CAGTATAAGCC39.
For the glycine to alanine, phenylalanine to tyrosine, leucine to
methionine triple mutation, sequential mutagenesis was performed
where the above-mentioned leucine mutation was used as the
template to generate an additional glycine to alanine mutation
using the primers:
sense: 59GGCTTATACTGCCTTGTTTATGCCTTCATG-
CCCAATGG39;
anti-sense: 59CCATTGGGCATGAAGGCATAAACAAGGC-
AGTATAAGCC39.
Finally, a phenylalanine to tyrosine mutation was generated
using the previously described double mutation as a template using
the primers:
sense: 59GGCTTATACTGCCTTGTTTATGCCTACATGC-
CCAATGG39;
anti-sense: 59CCATTGGGCATGTAGGCATAAACAAGGC-
AGTATAAGCC39.
All mutations were verified by sequencing the entire plasmid
using the T7 and SP6 primers (provided by Genome Quebec,
Montreal, QC, Canada) and the internal primers
59TTCCTCCACCAAGTCAAG39 and 59CCTGAGGAGTA-
CATCAAGAC39.
IL-12 mRNA expression analysis
RNA was extracted from MØs using TRIzol reagent (Invitro-
gen Canada, ON, Canada). Reverse transcription was performed
using oligodT. Quantitative Real-Time PCR (qRT-PCR) was
performed with a Corbett Research Rotorgene (Corbett Life
Science, Sydney, Australia), using Invitrogen Platinum SYBR
Green qPCR SuperMix-UDG (Invitrogen) and 0.4 mM primer in
25 ml. qPCR program is: 50uC 2 min; 95uC 3 min; (95uC 20 sec,
60uC 30 sec, 72uC 20 sec) for 40 cycles followed by a melting
curve. All primers annealing temperature was 60uC. Oligo
sequences are: GAPDH: 59-CGG ATT TGG CCG TAT TGG
GCG CCT-39 and 39- ACA TAC TCA GCA CCG GCC TCA
CCC-59; IL-12: 59- GGA AGC ACG GCA GCA GAA TA-39 and
39-AAC TTG AGG GAG AAG TAG GAA TGG-59.
TNF bioassay
TNF bioassay was performed as previously described [16].
Briefly, TNF-sensitive L929 fibroblasts were seeded in 96-well
plates in a concentration of 3.5610
4 cells/100 ml/well in RPMI-
1640 (5% FBS) medium and incubated for 24 h until obtaining a
monolayer. Supernatants from designated experiments were
added to L929 cells and serially diluted in the presence of
actinomycin D (2 mg/ml). After incubation (18–24 h, 37uC), the
L929 monolayers were stained with crystal violet, washed with
distilled water, and left to dry. Then, methanol was added to
dissolve the stain and cytotoxicity was determined by measuring
absorbance at 595 nm. One unit of TNF was referred to as the
reciprocal of the dilution that induced 50% of L929 cell lysis.
NO assay
NO production was evaluated by measuring the accumulation
of nitrite in the culture medium by the Griess reaction, as
previously described [3].
Electrophoretic mobility shift (EMSA)
Nuclear extracts were prepared by a standard protocol, and
EMSAs were performed as previously described [17]. Briefly,
nuclear extracts were incubated with binding buffer containing
1.0 ng of [c-
32P] dATP radiolabeled double-stranded DNA
oligonucleotide for 20 min at room temperature. The DNA binding
consensus sequence used for NF-kBw a s( 5 9-AGTTGAGGG-
GACTTTCCCAGGC-39).Sp1 consensusoligonucleotide wasused
as non-specific control (59-ATTCGATCGGGGCGGGGCGA-
GC-39) (Santa Cruz). DNA-protein complexes were resolved by
electrophoresis in native 4% (w/v) polyacrylamide gels. The gels
were then dried and autoradiographed.
pNPP phosphatase assay
MØs were collected, lysed in the PTP lysis buffer described
previously and kept on ice for 45 min. Lysates were cleared by
centrifugation, and protein content was determined by Bradford
reagent followed by IP. Equal amounts of IPs were incubated in a
phosphatase reaction mix (50mM Hepes (pH 7.5), 0.1% b-
mercaptoethanol, 10mM pNPP) overnight at 37uC. OD was then
read at 405 nm.
Sequence alignments
Sequences were obtained from the NCBI protein database.
Sequence alignments used to calculate identity and similarity
percentages were generated by EMBOSS local pair-wise alignment
Leishmania-Induced IRAK-1 Inactivation
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html). The accession numbers of the protein sequences included in
the study are: human (Homo sapiens) IRAK-1 (P51617), chimpanzee
(Pan troglodytes) IRAK-1 (XP_521332), dog (Canis familiaris)I R A K - 1
(XP_549367), bull (Bos Taurus)I R A K - 1( Q 2 L G B 3 ) ,m o u s e( Mus
musculus) IRAK-1 (Q62406), rat (Rattus norvegicus)I R A K - 1
(XP_001057078), tropical frog (Xenopus tropicalis) IRAK-1
(NP_001006713), zebrafish (Danio rerio) IRAK-1 (XP_697688),
human IRAK-4 (Q9NWZ3), chimpanzee IRAK-4
(XP_001166114), rhesus monkey (Macaca mulatta)I R A K - 4
(XP_001091707), dog IRAK-4 (XP_543727), bull IRAK-4
(Q1RMT8), mouse IRAK-4 (Q8R4K2), rat IRAK-4 (XP_217026),
chicken (Gallus gallus) IRAK-4 (NP_001025909), zebrafish IRAK-4
(AAT37635), squid (Euprymna scolopes) IRAK-4 (AAY27972), sea
urchin (Strongylocentrotus purpuratus) IRAK-4 (XP_784716), Caenorhabdi-
tis elegans IRAK-4 (NP_502587), honeybee (Apis mellifera) pelle-like
protein (XP_624002), Drosophila melanogaster pelle (NP_476971),
chicken IRAK-2 (NP_001025776), mouse JAK2 (Q62120), mouse
JAK3 (Q62137), mouse TAK1 (Q62073), mouse Erk1 (Q63844),
mouse Erk2 (P63085), mouse JNK (CAC88132), mouse p38
(P47811), mouse IKK-a (Q60680), mouse IKK-b (O88351), mouse
LYN (AAH31547).
Band quantification
All densitometric analyses were performed using the Quantity
One software, Biorad Laboratories Inc. Values and standard
deviations observed represent scans of three independent exper-
iments.
Ethical oversight
The bone marrow-derived macrophages described in this study
have been previously derived from WT and SHP-1 deficient mice
(see reference 7), and immortalized as cell lines. However,
experiments done on the animals used in that study (reference 7)
adhered to McGill University’s guidelines for animal husbandry
and was approved by the institutional research ethics committee.
Results
SHP-1 regulates IRAK-1 kinase activity by direct
interaction
To investigate the effect of SHP-1 on IRAK-1 kinase activity,
we immunoprecipitated IRAK-1 from the lysates of SHP-1
2/2
MØs and their wildtype (WT) counterparts and subjected the IP to
an IRAK-1 kinase assay. Results indicated that IRAK-1 kinase
activity in SHP-1
2/2 cells was significantly higher compared to
WT (Figure 1, top panel). The increase in IRAK-1 basal kinase
activity observed in SHP-1
2/2 cells is not due to a differential
expression of IRAK-1 as supported by loading controls provided
(Figure 1, lower panels).
Then, to evaluate whether the SHP-1 regulatory effect on
IRAK-1’s kinase activity involved their interaction, we performed
immunoprecipitation assays and observed that IRAK-1 and SHP-
1 co-IP (Figure 2A). Their association was further confirmed as we
have detected PTP activity corresponding to SHP-1 in the IRAK-
1 IP (Figure 2B, top panel), and IRAK-1 kinase activity in the IP of
SHP-1 (Figure 2B, bottom panel). A secondary rat antibody was
used as a negative control (Figures 2A and B). These experiments
suggested the presence of IRAK-1 and SHP-1 in the same multi-
protein complex. To test whether they directly interact, we in vitro
translated IRAK-1 using radiolabelled methionine, and put the
radiolabelled IRAK-1 in contact with GST-SHP-1. IRAK-1 was
pulled down specifically by GST-SHP-1 and not by GST alone,
showing that this interaction is direct (Figure 2C).
Next, we examined whether the binding of SHP-1 is sufficient to
regulate IRAK-1 kinase activity. To do so, IRAK-1 was
immunoprecipitated and put in contact with increasing concen-
trations of active GST-SHP-1. IRAK-1 kinase activity was
inhibited in a dose-dependent manner by GST-SHP-1 and not
by GST alone (Figure 2D, left panel). Interestingly, the highest
dose of GST-SHP-1 used to inhibit IRAK-1 activity did not alter
IRAK-4’s kinase activity (Figure 2D, right panel).
The fact that the PTP-SHP-1 dephosphorylates tyrosyl residues
raised the possibility that IRAK-1 is tyrosine phosphorylated. To
investigate this hypothesis, alkali-resistance phosphoprotein assays
were performed. Treatment of IRAK-1 kinase assay gels with
KOH permits the in-gel dephosphorylation of pSer and pThr, but
not pTyr allowing us to evaluate the contribution of tyrosine
phosphorylation to the overall phosphorylation signal. Although
IRAK-1 is known to be phosphorylated on Ser/Thr residues [18],
our results represent the first demonstration that IRAK-1 is also
tyrosine phosphorylated in the resting state, and that LPS
increases IRAK-1 tyrosyl phosphorylation by 46615% SD
(Figure 2E, upper panels). This finding was further confirmed by
western blot using the 4G10 pTyr-specific antibody (Figure 2E,
lower two panels).
SHP-1 binds to the kinase domain of IRAK-1 via an ITIM-
like motif
At the view of our observations, we screened the mouse IRAK-1
sequence for possible SHP-1 binding sites. We discovered that
IRAK-1 contains an ITIM-like motif (286LVYGFL291) located in
its kinase domain (Figure S1). This motif was found to be absent in
all the other IRAK family members since the last residue is a
methionine instead of a leucine (Figure S2). To determine the
involvement of this ITIM-like motif in the SHP-1/IRAK-1
binding, we used the full-length IRAK-1 sequence to introduce
site-specific mutations within the motif followed by in vitro binding
assays (Figure 3). Firstly, a Y288F mutation slightly decreased
SHP-1 binding suggesting that possible phosphorylation of the
motif’s central tyrosine may increase binding affinity but is not
absolutely necessary for the binding to occur. Secondly, an L291M
mutation, which renders the site no more ITIM-like, significantly
decreased SHP-1 binding. Thirdly, the G289A/F290Y/L291M
Figure 1. Regulation of IRAK-1 kinase activity by SHP-1. Upper
Panel represents an in vitro kinase assay comparing the basal kinase
activity of IRAK-1 in WT littermates versus Ptpn6
me/me MØ (SHP-1
2/2). A
fraction of the IP was kept and subjected to a western blot as a control
for equal IRAK-1 IP (2
nd panel from top). Cell lysates of WT and SHP-1
2/2
MØs were blotted for SHP-1 to demonstrate the presence/absence of
the SHP-1 protein (3
rd panel from top). The membrane was stripped
and reblotted for IRAK-1 to monitor its expression level in both cell lines
(4
th panel from top). Actin levels are shown as loading controls (bottom
panel). All results are representative of at least three independent
experiments.
doi:10.1371/journal.pntd.0000305.g001
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completely abrogated the binding of SHP-1. Interestingly, this
triple mutant of IRAK-1 is identical to the corresponding site
within IRAK-4. Collectively, these site-specific mutations confirm
the role of the ITIM-like motif in the binding of SHP-1 to IRAK-
1. This represents the first description of such a motif in a kinase
that we now call KTIM (Kinase Tyrosyl-based Inhibitory Motif).
Importantly, these experiments also suggest that the SHP-1-
mediated regulation of IRAK-1 is a mechanism not shared with
IRAK-4.
Leishmania inhibits LPS-mediated MØ functions by
rapidly inactivating IRAK-1
The biological relevance of this regulatory interaction between
IRAK-1 and SHP-1 was investigated using the ability of N-(2-
Morpholinylethyl)-2-(3-nitrobenzoylamido)-benzimidazole, a po-
tent IRAK-1 inhibitor [19], to reduce NO production in WT and
SHP-1
2/2 MØs. As mentioned earlier, SHP-1 deficiency in MØs
results in an increase in NF-kB and AP-1 activity [7–9] leading to
NO production at basal level and in response to LPS when
Figure 2. Demonstration of the IRAK-1/SHP-1 interaction. (A) Western blot analysis demonstrating the Co-IP of IRAK-1 and SHP-1. IRAK-1 and
SHP-1 were immunoprecipitated then blotted against SHP-1 and IRAK-1 antibodies. Rabbit IgG anti-rat was used as a control. (B) In gel PTP activity
assay of SHP-1 and IRAK-1 IPs (top blot). Rabbit IgG anti-rat was used as an IP control. Cell lysates of WT and SHP-1
2/2 were added in the last two
lanes to confirm that the signal was SHP-1. Lower blot represents IRAK-1 kinase activity in reciprocal IPs. (C) In vitro transcription/translation of the
IRAK-1 gene was performed using radiolabelled methionine. First lane shows the IRAK-1 input. The last two lanes show methionine-labelled IRAK-1
pulled down after 1 h incubation with either a GST-SHP-1 or GST respectively. (D) Kinase assay measuring IRAK-1 activity upon its interaction with
either GST alone or increasing concentrations of an active GST-SHP-1 construct (left panel). Kinase assay measuring IRAK-4 activity (right panel) upon
its interaction with either GST alone or GST-SHP-1 (5 mg). (E) Kinase assay showing IRAK-1 activity at basal level and upon LPS treatment subjected to
alkali treatment to evaluate tyrosine phosphorylation in IRAK-1. Tyrosyl phosphorylation was confirmed by western blot using an anti-
phosphotyrosine antibody. An IP fraction was kept and blotted for IRAK-1 as a loading control.
doi:10.1371/journal.pntd.0000305.g002
Figure 3. Mutation of IRAK-1’s KTIM abrogates its ability to
bind SHP-1. Top panel represents methionine-labelled WT-IRAK-1 as
well as the different IRAK-1 mutants in vitro translated and put in
contact with 5 mg of either GST alone or a trapping GST-SHP-1
construct. Bottom panel represents equal fractions of the in vitro
translated products ran on an SDS gel to show equal input. All results
are representative of at least three independent experiments.
doi:10.1371/journal.pntd.0000305.g003
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IRAK-1 activity in a dose-dependent manner (Figure 4A), and was
paralleled by a reduction of basal NO production in SHP-1
2/2
cells and in LPS-mediated NO production in both cell lines
(Figure 4B). In addition to demonstrating the essential role of
IRAK-1 signalling in NO generation, our data also shows that
SHP-1-mediated IRAK-1 regulation is critical for the control of
MØ activation.
Using Leishmania as an infectious model, we studied its ability to
inhibit key MØ LPS-mediated functions namely: IL-12 expression,
TNF production, and NO generation. Our results confirmed that
infection with Leishmania caused a significant inhibition of LPS-
mediated expression of IL-12 (Figure 5A), TNF production
(Figure 5B), and NO generation (Figure 5C) in MØs.
As Leishmania activates host SHP-1 and blocks many LPS-
mediated functions known to be detrimental to the parasite, we
investigated the possibility that Leishmania inactivates IRAK-1.
Kinase assays comparing IRAK-1 activity in MØs infected with L.
donovani to uninfected cells revealed that the parasite caused a
rapid time-dependent inactivation of IRAK-1 seen by reduced
basal IRAK-1 activity in infected MØs (Figure 6A). To investigate
whether IRAK-1 inactivation is a common mechanism utilized by
other infectious Leishmania species, MØs were infected for 1 h with
various Leishmania species promastigotes and IRAK-1 kinase
activity was measured. L. donovani decreased IRAK-1 activity by
65611% SD, and consistent with our expectation, L. mexicana and
L. major were also able to inactivate IRAK-1 as they decreased
IRAK-1 kinase activity by 6567% SD and 5264% SD,
respectively (Figure 6B). Interestingly, L. tarentolae, a lizard non-
pathogenic Leishmania did not inhibit IRAK-1 and seemed to even
slightly activate it (increase of 20611% SD).
In light of these observations, we were interested to evaluate
whether the Leishmania-mediated IRAK-1 kinase inactivation
could alter LPS-mediated functions in infected MØs. Our results
indicated that unlike LPS stimulation per se that activates IRAK-1,
infection with Leishmania rendered IRAK-1 activation refractory to
this TLR4 agonist (Figure 6C). Since IRAK-1 signals downstream
of all TLRs with the exception of TLR3, we investigated whether
this Leishmania-induced IRAK-1 inactivation is persistent upon
stimulation with other TLR ligands. As expected, Leishmania was
able to render IRAK-1 unresponsive to MALP (TLR2), flagellin
(TLR5), and CpG (TLR9) (Figure 6D). These results suggest that
alteration of IRAK-1-dependent signalling by Leishmania causes a
general unresponsiveness to a broad range of TLR ligands. All
TLR ligands used were shown to be functional using an NF-kB
nuclear translocation assay (Figure S3).
Leishmania infection enhances the IRAK-1/SHP-1
interaction leading to IRAK-1 inactivation
Having previously reported that Leishmania can rapidly induce
host PTP SHP-1 to inactivate JAK and MAP kinase pathways
[8,20], we hypothesized that the Leishmania-induced IRAK-1
inactivation observed was associated with an increased SHP-1/
IRAK-1 interaction. We indeed noticed by Western blot that a
significantly greater amount of SHP-1 was co-immunoprecipitated
with IRAK-1 upon Leishmania infection (Figure 7A). Similarly,
using in gel PTP assay, we were able to detect more SHP-1 activity
in IRAK-1 IP from lysates of Leishmania-infected MØs (Figure 7B).
Higher SHP-1 activity in Leishmania infected MØs was further
supported when equal IP fractions were subjected to a pNPP
phosphatase assay (Figure 7C).
To demonstrate that the increased SHP-1/IRAK-1 binding
upon Leishmania infection is responsible for IRAK-1 inactivation,
IRAK-1 kinase activity was monitored in infected WT and SHP-
1
2/2 MØs. In accordance with our finding in B10R MØs
(Figure 6), Leishmania was able to inactivate IRAK-1 in WT MØs
(6769% SD decrease in IRAK-1 activity). Interestingly, this
Leishmania-induced inactivation was not detected in the absence of
SHP-1 (266% SD decrease in IRAK-1 activity) (Figure 7D). This
rescue of IRAK-1 activity was correlated with an inability of the
parasite to block LPS-induced NO production in SHP-1
2/2 MØs
(Figure 7E). Collectively, this set of data shows that the Leishmania-
activated SHP-1 is responsible for IRAK-1 inactivation leading to
the unresponsiveness of infected MØs to LPS stimulation.
To further understand the impact of IRAK-1 inactivation on
LPS-mediated activation in infected MØs, we monitored the
association and dissociation events of IRAK-1 with known key
signalling molecules (MyD88, TRAF6) in response to LPS in naı ¨ve
and Leishmania-infected cells. The result showed that IRAK-1
inactivation by Leishmania-induced SHP-1 is associated with the
inability of IRAK-1 to detach from MyD88 and attach to TRAF6
in response to LPS stimulation (Figures 7F and G).
IRAK-1 and SHP-1 emerged in early vertebrates while
IRAK-1 KTIM appeared only in amphibians
Given the important regulatory function of the KTIM present
within IRAK-1, we speculated that it would be evolutionarily
conserved. In silico sequence comparisons of available IRAK-1
sequences revealed that KTIM (LVYGFL) was fully conserved
from rodents to human (Figure 8). However, while the KTIM in
Xenopus tropicalis showed some variations compared to the other
vertebrate sequences (LIYLYL), it was absent in zebrafish due to
the presence of a methionine at the last position (VIYVYM). Next,
we addressed the origin of IRAK-1 and SHP-1 as they are only
Figure 4. Effect of pharmacological inhibition of IRAK-1 on MØ
NO production. (A) IRAK-1 was immunoprecipitated from SHP-1
2/2
MØ lysates and incubated (1 h, RT) with increasing concentrations of
the IRAK-1 inhibitor. A kinase assay was then performed to show
functionality of the inhibitor. Data are representative of three
experiments. (B) NO assay showing that the IRAK-1 inhibitor blocks, in
a dose-dependent manner, basal production of NO by SHP-1
2/2 cells as
well as LPS-mediated (O/N stimulation) NO production in both WT and
SHP-1
2/2 MØs.
doi:10.1371/journal.pntd.0000305.g004
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available IRAK-4 sequences from vertebrates and invertebrates
(Figure S4), indicate that IRAK-1 evolved from IRAK-4 by gene
duplication (Figure 9A). Similar sequence similarity comparisons
suggest that SHP-1 evolved from SHP-2 and its orthologues found
in invertebrates and that the ancestral SHP-1 gene also appeared
through gene duplication in lower vertebrates (zebrafish)
(Figure 9B).
From these observations, we raised the question whether other
kinases may also have a KTIM within their kinase domain.
Although several proteins involved in MyD88-dependent signal-
ling (e.g. MyD88, TIRAP, TRAF6) did not contain KTIMs in
their amino acid sequence (data not shown), we were intrigued to
discover that several kinases from the JAK, MAP, Src, and IKK
kinase families (JAK2, JAK3, Erk1/2, JNK, p38, Lyn, IKKa/b)
contained one or more potential KTIMs, the majority located
within their kinase domains (Figure 10A). This finding raises the
possibility that KTIMs play important regulatory functions for
many kinases by favoring their interaction with SHP-1, as we
herein report for IRAK-1. SHP-1 binding may control the activity
of these kinases at resting state or regulate their activity upon
activation. In gel phosphatase assays that we performed support
this possibility as they demonstrate that IPs of IKK-b, Erk, JNK,
and p38 indeed exhibit SHP-1 activity (Figure 10B), indicating
that these kinases interact with SHP-1. Interestingly, Syk – a
kinase that has no KTIM in its amino acid sequence – did not
show interaction with SHP-1 at resting state.
Discussion
Leishmania has been reported to inhibit critical LPS-mediated
MØ functions such as NO and pro-inflammatory cytokines (e.g.
IL-12 and TNF) production [2,4,5]. Although mechanisms
whereby NO is inhibited by Leishmania in response to IFN-c have
been well explored [2], our knowledge concerning the negative
regulatory mechanisms leading to the down-regulation of LPS-
Figure 5. Inhibition of LPS-mediated functions by Leishmania. (A) LPS-mediated MØ IL-12 mRNA expression was analyzed by RT-PCR in
uninfected and Leishmania-infected MØs. Cells were infected with L. donovani O/N followed by LPS stimulation (10 and 100 ng/ml, 12 h). (B) LPS-
mediated TNF production by MØs infected with Leishmania. Cells have been infected as above and stimulated with LPS for 3 h. (C) NO production by
Leishmania-infected MØs in response to LPS. Cells have been infected as above and stimulated with LPS for 24 h. (A–C) *, significant at P,0.05, Anova
test, error bar SEM. Mean of three independent experiments.
doi:10.1371/journal.pntd.0000305.g005
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Herein, we provide the first demonstration that the Leishmania
parasite can rapidly inactivate IRAK-1 kinase activity with the
participation of SHP-1, therefore inhibiting MØ LPS-mediated
functions. We further reveal that the mechanism by which this
inactivation occurs is through the binding of SHP-1 to an
evolutionarily-conserved ITIM-like motif located in the kinase
domain of IRAK-1. This is the first demonstration that a pathogen
can use a host PTP to inactivate IRAK-1 and therefore block
signalling pathways ultimately leading to free radicals and pro-
inflammatory cytokines production known to be detrimental to its
survival.
Given that TNF is a potent MØ activator, NO is leishmanicidal,
and IL-12 is a critical cytokine that drives Th1 responses essential
for the development of immunity against Leishmania, it is not
surprising that the parasite has evolved means to block the
production of these molecules [2]. A role for Leishmania
phosphoglycans (PG) has been proposed in the inhibition of NO
[21]. In addition, roles for promastigote PG [22,23] and
amastigote cysteine peptidases [24] in the inhibition of LPS-
mediated IL-12 production have been reported. Nevertheless,
apart from very few reports about Leishmania-induced alterations in
the Erk MAPK [22] and the downstream transcription factor NF-
kB [24], very little is known about how LPS-mediated functions
are inhibited by Leishmania. In this study, we confirmed that all
three LPS-mediated MØ functions were inhibited by Leishmania.
Importantly, looking at NO production as a key function involved
in the killing of Leishmania parasites, we were able to show that
IRAK-1 signalling is key for its production. In fact, our finding
that Leishmania inactivates IRAK-1 kinase activity and that this
inactivation is persistent upon subsequent LPS-stimulation sup-
ports the fact that the parasite is able to successfully block LPS-
mediated NO production in MØs. Interestingly, consistent with
the fact that IRAK-1 signals downstream of many TLRs, we
showed that IRAK-1 was also unresponsive in Leishmania–infected
cells subjected to stimulation with TLR2, TLR5, and TLR9
ligands. This result suggests that the parasite causes wide range
unresponsiveness to TLR signalling upon infection possibly
allowing Leishmania to avoid any harmful MØ activation involving
TLR engagement. Interestingly, L. donovani has been shown to
activate IRAK-1 in IFN-c-primed MØs [25] suggesting that the
activation state of the MØ can play an important role in the ability
of the parasite to inactivate IRAK-1. In an effort to understand
how Leishmania inactivates IRAK-1, we were able to identify SHP-
1 as a key player in this process as there was almost a complete
rescue of IRAK-1 activity in SHP-1
2/2 MØs infected with
Leishmania. This rescue was corroborated by the parasite’s inability
to block LPS-mediated NO production in SHP-1
2/2 MØs. These
results suggest a new evasion mechanism whereby Leishmania can
avoid detrimental MØ functions driven by MyD88-dependent
pathways by blocking IRAK-1, a key kinase in this pathway.
Our observation that the Leishmania–mediated IRAK-1 inacti-
vation was associated with enhanced SHP-1 binding to IRAK-1
fits with our finding that SHP-1 binds to and regulates IRAK-1 at
resting state. We clearly showed that IRAK-1’s intrinsic kinase
activity was higher in SHP-1
2/2 compared to WT MØs
identifying SHP-1 as a novel regulator of IRAK-1 activity, a
finding supported by recent work of Cao and colleagues [11]. The
fact that SHP-1 interacts with and also dephosphorylates tyrosyl
residues raised the possibility that IRAK-1 is tyrosine phosphor-
ylated. Here, we show that IRAK-1 is indeed tyrosine phosphor-
ylated at resting state, and further so in response to LPS
stimulation. Given that IRAK-1 was previously shown to be
phosphorylated on Ser/Thr residues only [18], our findings
represent the first demonstration that IRAK-1 is also tyrosine
phosphorylated.
Having identified an ITIM-like motif in the kinase domain of
IRAK-1 as the binding site of SHP-1, its functionality was
demonstrated by generating mutations within the motif providing
valuable information about the role of its amino acid components
in the binding affinity of SHP-1. Firstly, the tyrosine to
phenylalanine (Y288F) mutation suggested that the phosphoryla-
tion of the motif’s central tyrosine is not necessary for the binding
of SHP-1 to occur. Indeed it has been previously reported that
tyrosyl phosphorylation within ITIMs is not always required for
the binding of SH2-domain containing proteins [26]. Secondly,
the observation that the G289A-F290Y-L291M mutation caused a
total abrogation of SHP-1 binding, and that the L291M mutation
partially reduced binding suggested that the amino acids between
the central tyrosine and the terminal leucine in the motif play an
important role in the binding affinity of SHP-1. Lastly, as the triple
mutant was designed to render the ITIM-like site in IRAK-1
identical to its corresponding site in IRAK-4, the loss of SHP-1
binding in this mutant suggested that the SHP-1-mediated
regulation of IRAK-1 is a regulatory mechanism not shared with
IRAK-4. It is noteworthy to emphasize that ITIMs have been
named so due to their presence in intracytoplasmic portions of
transmembrane receptors [27]. Given that here we describe this
motif to be found in a cytosolic kinase and show that it mediates
SHP-1 binding and IRAK-1negative regulation, we propose to
rename it KTIM (Kinase Tyrosyl-based Inhibitory Motif).
In MyD88-dependent signalling pathways, binding of TLR
ligand to its corresponding receptor causes a rearrangement of the
Figure 6. Inhibition of LPS-induced IRAK-1 kinase activity by
Leishmania. (A) Kinase assay performed on IRAK-1 IPs from lysates of
MØs uninfected and infected with L. donovani over a 6 h time-period.
LPS stimulation (100 ng/ml, 30 min), positive control. (B) IRAK-1 kinase
activity detected in IPs from lysates of MØs infected or not with
pathogenic Leishmania species (L. donovani, L. mexicana, L. major) (20:1
parasite to cell ratio, 1 h). Non-pathogenic lizard L. tarentolae was used
as negative control. (C) Kinase assay of IRAK-1 IPs from lysates of naı ¨ve
and L. donovani-infected MØs (O/N infection) subjected or not to LPS
stimulation (100 ng/ml, 30 min). (D) IRAK-1 kinase activity in IPs from
naı ¨ve and L. donovani-infected MØs (O/N infection) stimulated or not
with various TLR ligands (MALP (100 ng/ml), LPS (100 ng/ml), flagellin
(100 ng/ml), CpG (5 mg/ml); 30 min). All results are representative of at
least three independent experiments.
doi:10.1371/journal.pntd.0000305.g006
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protein MyD88, which in turn recruits the kinases IRAK-4 and
IRAK-1 to the receptor complex [1]. Upon critical phosphory-
lations of IRAK-1 by IRAK-4 [18], IRAK-1 is partially activated
and is able to get fully activated by autophosphorylation. This
autophosphorylation causes IRAK-1 to detach from the MyD88
complex and attach to TRAF6 activating downstream signalling
pathways. Therefore, the IRAK-1 inactivation by Leishmania-
induced SHP-1 had to interfere somehow with the integrity of the
previous signalling events. Of utmost interest, we have been able to
show that although IRAK-1 was still able to bind MyD88 in
Leishmania-infected MØs in response to LPS stimulation, the kinase
was unable to detach from the MyD88 complex and bind to
TRAF6 as the stimulation persisted. This is the first demonstration
that a pathogen can interfere with Toll signalling by altering
IRAK-1’s capacity to dissociate from the MyD88 complex. This
inability of IRAK-1 to detach from MyD88 is supported by our
observation that the binding of Leishmania-induced SHP-1 to the
kinase domain of IRAK-1 causes a strong inactivation of this
kinase seen by its inability to autophosphorylate, a process
required for IRAK-1 to detach from the receptor complex and
activate downstream signalling cascades.
Finally, it was remarkable to find out that the KTIM in IRAK-1
was evolutionarily conserved from human to rodents. The absence
of KTIM in fish and its appearance in amphibians suggests that
this motif emerged rapidly after the appearance of the ancestral
IRAK-1 gene in early branching vertebrates (amphibians) and was
highly conserved thereafter (Figure S5). Our findings thus raise the
possibility that during the course of evolution, the emergence of a
mechanism to regulate the innate immune response by targeting
IRAK-1 activity (e.g. SHP-1) may have favoured the development
of a more sophisticated adaptive immune system in higher
vertebrates (Figure S5). In addition, it is important to note that
Toll-Interacting Protein (TOLLIP) [28], the only other negative
regulator of IRAK-1 in the resting state has emerged very early in
invertebrates as opposed to SHP-1 [29], IRAK-1 [30] and the
KTIM motif which all appeared only in early vertebrates.
Noteworthy, we found that several other kinases from the JAK,
MAP and IKK kinase families contained one or more potential
KTIMs raising the possibility that KTIMs play important
regulatory functions in many kinases (other than IRAK-1) by
favouring their interaction with SHP-1. In fact, it has been
previously reported that some of these kinases (e.g. JAK2, JAK3,
JNK, Erk1/2) are negatively regulated by SHP-1 [31–33].
Figure 7. IRAK-1/SHP-1 interaction is enhanced by Leishmania infection and leads to IRAK-1 signalling alteration and MØ functional
inhibition. (A) Western blot analysis demonstrating the enhanced co-IP of IRAK-1 and SHP-1 in response to Leishmania infection. IRAK-1 was
immunoprecipitated from uninfected and Leishmania-infected MØ lysates (30 min post-infection). The IPs were run on SDS-PAGE and blotted against
SHP-1 (upper panel). Membrane was then stripped and blotted against IRAK-1 as a control for equal IP (lower panel). (B) A fraction of the IPs (a, upper
panel) was subjected to in gel PTP assay showing higher SHP-1 activity associated with the IP of Leishmania-infected MØs over uninfected. (C)
Fraction of the IP (a, upper panel) was also subjected to a phosphatase assay based on pNPP hydrolysis demonstrating a significantly higher total
phosphatase activity in the IP of Leishmania-infected cells compared to uninfected controls. *, P,0.05; error bar SD. Data are the mean of four
independent experiments. (D) IRAK-1 kinase assay of WT and SHP-1
2/2 MØs infected or not with L. donovani for 1 h (upper panel). IP fraction was
kept and subjected to western blot as a loading control of IRAK-1 immunoprecipitation (lower panel). (E) NO production by Leishmania-infected WT
and SHP-1
2/2 MØs in response to LPS. Cells have been infected with L. donovani (O/N) and stimulated with LPS for 24 h. Significant difference
P,0.05, Anova test, error bar SEM. Mean of three independent experiments. (F and G) IRAK-1 Inactivation by Leishmania causes its inability to bind
TRAF6. Western blot analysis showing that Leishmania causes an abrogation of the ability of IRAK-1 to bind TRAF6, but not MyD88, upon LPS
stimulation. IRAK-1 was immunoprecipitated from lysates of naı ¨ve and L. donovani-infected MØ (1 h infection) stimulated or not with LPS (100 ng/ml,
1 h). The IPs were run on SDS-PAGE and blotted against MyD88 (F) and TRAF6 (G). Membranes were stripped and blotted against IRAK-1 to
demonstrate equal IP.
doi:10.1371/journal.pntd.0000305.g007
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is conserved in all vertebrates down to Xenopus tropicalis (amphibian) but is absent in Danio rerio (zebrafish). All homology percentages were
calculated using the human IRAK-1 sequence as a reference. Human: Homo sapiens; Chimpanzee: Pan troglodytes; Dog: Canis familiaris; Bull: Bos
Taurus; Mouse: Mus musculus; Rat: Rattus norvegicus.
doi:10.1371/journal.pntd.0000305.g008
Figure 9. Evolution of vertebrate IRAK-1 and SHP-1 from IRAK-4 and SHP-2 ancestor genes. Schematic representation of the appearance
of IRAK-1 and SHP-1 from gene duplication events of the IRAK-4 (A) and SHP-2 (B) ancestor genes, respectively. The emergence of the KTIM in IRAK-1
occurred after this gene duplication event took place as the motif only appeared in amphibians. Similarity percentages were calculated using the
mouse IRAK-1 and IRAK-4 sequences.
doi:10.1371/journal.pntd.0000305.g009
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mechanism whereby SHP-1 either interacts or regulates these
kinases. It remains to be mentioned that whereas some of these
kinases are also present in invertebrates, IRAK-1 and its KTIM
only appeared in vertebrates. This observation supports the idea
that the appearance of this motif in IRAK-1 has favoured the
development of a mechanism to control the innate immune
response. In this context, regulation of IRAK-1 kinase activity
would have prevented abnormal and exacerbated microbicidal
and inflammatory immune responses that could have been
detrimental to vertebrates and to the development of the adaptive
immune response. It is also tempting to speculate that the
appearance of an improved control over kinases by SHP-1 may
have influenced the global development of vertebrates, as several
of these kinases play pivotal roles in the regulation of cellular,
molecular, developmental, and metabolic processes.
In conclusion, we have identified a new evasion mechanism
whereby Leishmania-activated SHP-1 binds to an evolutionarily
conserved KTIM located in IRAK-1’s kinase domain leading to its
inactivation. This abrogation was associated with the inability of
IRAK-1 to detach from the MyD88 complex to bind TRAF6,
consequently resulting in the unresponsiveness of Leishmania-
infected macrophages to several TLR ligand stimulation including
LPS. By doing so, the parasite is not only able to block LPS-
mediated MØ production of NO and pro-inflammatory cytokines
known to be involved in Leishmania killing, but also terminate the
extremely important roles played by these molecules in the
development of an effective adaptive immune response. At the
evolutionary level, we propose that the appearance of SHP-1 as a
key regulator of IRAK-1 kinase activity represented a pivotal
evolutionary step that could have favoured the development of the
adaptive immune response in vertebrates.
Supporting Information
Figure S1 IRAK-1 contains a KTIM motif in its kinase domain.
The full amino acid sequence of mouse IRAK-1 has been obtained
from the NCBI protein database (Ref. no. Q62406). The newly
identified KTIM is in violet. Bottom drawing is a schematic
representation of the IRAK-1 protein showing the locations of the
different domains and critical residues. KTIM motif is shown as a
violet rectangle. ProST, Proline/Serine/Threonine -rich.
Found at: doi:10.1371/journal.pntd.0000305.s001 (1.56 MB TIF)
Figure S2 Among the IRAK family, KTIM is unique to IRAK-
1. All other IRAK family members (IRAK-2, IRAK-M, and
IRAK-4) whose sequences are available for various invertebrate
and vertebrate organisms lack a KTIM. A sequence comparison in
the KTIM region among the different IRAK family members is
shown. Mouse was chosen as a representative organism.
Found at: doi:10.1371/journal.pntd.0000305.s002 (0.38 MB TIF)
Figure S3 TLR ligands activate NF-kB in stimulated MØs. Gel
represents an electromobility shift assay (EMSA) showing NF-kB
nuclear translocation in response to a 2 h stimulation with the
different TLR ligands used in Figure 6D. The EMSA confirms
that the ligands are functional and activating at the concentrations
used. MALP, Macrophage-activating lipopeptide-2. Flag, Flagel-
lin. S, Specific competition (1006 cold oligo). NS, Non-specific
competition (SP1 oligo).
Found at: doi:10.1371/journal.pntd.0000305.s003 (0.19 MB TIF)
Figure S4 IRAK-4 shows homology to IRAK-1 but does not
bear a KTIM due to a single amino acid substitution. IRAK-4
sequence comparison of various vertebrates and invertebrates
reveal that IRAK-4 has no KTIM due to a single leucine to
methionine/isoleucine substitution. All IRAK-4 homology per-
centages were calculated using the human IRAK-4 sequence as a
reference. IRAK-1/IRAK-4 homology percentages were calcu-
lated within the same species. Rhesus monkey: Macaca mulatta;
Chicken: Gallus gallus; Squid: Euprymna scolopes; Sea urchin:
Strongylocentrotus purpuratus; Worm: Caenorhabditis elegans; Honeybee:
Apis mellifera; Fly: Drosophila melanogaster.
Found at: doi:10.1371/journal.pntd.0000305.s004 (1.72 MB TIF)
Figure S5 Regulation of IRAK-1 by SHP-1 through its binding
to KTIM is unique to vertebrates and may have favoured the
development of their adaptive immune response. Schematic
representation of the emergence of IRAK-1 and SHP-1 from
IRAK-4 and SHP-2, respectively. Unlike TOLLIP and SHP-2
which are found in invertebrates, SHP-1 arose in vertebrates just
like IRAK-1 and KTIM, coinciding with the emergence of the
adaptive immune response.
Found at: doi:10.1371/journal.pntd.0000305.s005 (1.54 MB TIF)
Alternative Language Abstract S1 Translation of the Abstract
into Arabic by Issa Ayoub Abu-Dayyeh
Found at: doi:10.1371/journal.pntd.0000305.s006 (0.02 MB
DOC)
Alternative Language Abstract S2 Translation of the Abstract
into French by Marceline Co ˆte ´
Found at: doi:10.1371/journal.pntd.0000305.s007 (0.02 MB
DOC)
Figure 10. Several kinases possess KTIMs. (A) Table showing that
several kinases from the JAK, MAP, Src, and IKK kinase families possess
potential KTIMs in their amino acid sequences. Screening was done
using published mouse protein sequences found in the NCBI protein
database. (B) An in gel phosphatase assay (upper panel) demonstrating
that IPs of IKK-b, Erk1/2, JNK, and p38 all exhibit SHP-1 activity. Syk IP
was added as a control for a kinase that has no KTIM in its sequence and
rabbit IgG was used as a negative control. Fractions of all IPs were kept
and run on SDS-PAGE and blotted against their corresponding antibody
to demonstrate the success of the IP procedure (lower panel).
doi:10.1371/journal.pntd.0000305.g010
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